Article in Nature Biotechnology about our new name and plans for the future (subscription needed to read full text).
LifeArc splashes out, fuelled by Keytruda (pembrolizumab)
Articles
Related news
First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization Expertise
LifeArc monetises Keytruda® royalty interests to fund further research and investment